These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 17511690

  • 1. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
    Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F.
    Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
    [Abstract] [Full Text] [Related]

  • 2. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 3. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.
    Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG.
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):287-91. PubMed ID: 19835968
    [Abstract] [Full Text] [Related]

  • 4. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 5. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 6. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 7. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 8. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ.
    Blood; 2002 Jun 15; 99(12):4364-9. PubMed ID: 12036863
    [Abstract] [Full Text] [Related]

  • 9. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.
    Eur J Pediatr; 2014 Dec 15; 173(12):1615-8. PubMed ID: 24169729
    [Abstract] [Full Text] [Related]

  • 10. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY.
    Transpl Infect Dis; 2019 Dec 15; 21(6):e13182. PubMed ID: 31556214
    [Abstract] [Full Text] [Related]

  • 11. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
    De Pasquale MD, Mastronuzzi A, De Vito R, Cometa A, Inserra A, Russo C, De Ioris MA, Locatelli F.
    Pediatrics; 2012 Jan 15; 129(1):e189-94. PubMed ID: 22144701
    [Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M.
    Rev Med Virol; 2020 Jul 15; 30(4):e2108. PubMed ID: 32301566
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
    Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.
    Leuk Lymphoma; 2019 Jul 15; 60(7):1693-1696. PubMed ID: 30741059
    [Abstract] [Full Text] [Related]

  • 14. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation.
    Yedibela S, Reck T, Niedobitek G, Gramatzki M, Repp R, Hohenberger W, Ott R.
    Transpl Int; 2003 Mar 15; 16(3):197-201. PubMed ID: 12664216
    [Abstract] [Full Text] [Related]

  • 15. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
    Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A.
    Pediatr Int; 2017 Sep 15; 59(9):973-978. PubMed ID: 28581032
    [Abstract] [Full Text] [Related]

  • 16. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 15; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 17. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 15; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 18. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
    Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, Piantadosi S, Caligiuri MA, Ambinder RF.
    Blood; 2000 Dec 15; 96(13):4055-63. PubMed ID: 11110673
    [Abstract] [Full Text] [Related]

  • 19. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.
    Reddy N, Rezvani K, Barrett AJ, Savani BN.
    Biol Blood Marrow Transplant; 2011 May 15; 17(5):591-7. PubMed ID: 20732435
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 15; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.